Analysts have distinguished a novel applicant opposition mutation that decreased venetoclax binding in a patient with relapsed/refractory follicular lymphoma treated with venetoclax. In spite of the fact that the male patient, matured 55 years, at first reacted to venetoclax as part of a stage 1 clinical preliminary, after 29 months on therapy, his disease repeated. […]
